

ASX Announcement

23 September 2021

InvestorStream Interview - Presentation

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to provide a copy of the presentation by CEO Derek Thomson for the InvestorStream interview. [ASX 17 September 2021 Investor Webinar Invitation]

The webinar will be made available on the Company's website and InvestorStream's YouTube channel as well as AnteoTech's social media platforms this afternoon.

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

About AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/Anteotech> or visit www.anteotech.com





AnteoTech Ltd (ASX:ADO)

Investor Update

23 September 2021

Derek Thomson, CEO

DISCLAIMER



The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside AnteoTech Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and AnteoTech's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by AnteoTech Ltd. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

EuGeni SARS-CoV-2 Ag RDT – CE Marked - not available in other jurisdictions

- The COVID-19 rapid antigen test (RAT) must not be supplied for the purpose of self-testing
- The COVID-19 rapid antigen test must only be used by relevant practitioners, or persons under their supervision, who are trained in the correct use of the goods and the interpretation of the test results
- Negative test results do not exclude infection with COVID-19 (so face masks, social distancing and good hygiene practice must be maintained)
- Positive test results or symptomatic persons require immediate confirmatory testing with a polymerase chain reaction (PCR) test.




AnteoTech

Life Science

EUGENI LEVERAGING THE PLATFORM




Our vision is to leverage the EuGeni platform across multiple markets, creating multiple revenue streams.



EUGENI – COVID-19 RAT - SIGNIFICANT PROGRESS IN 18 MONTHS



- Average cost and time for developing and bringing to market a Point of Care Diagnostics Platform is \$34M and six years.¹
- EuGeni development costs to date a fraction of the industry benchmark.
- Development timelines accelerated by leveraging AnteoBind technology and deep conjugation expertise.
- Time to market accelerated by careful selection of technology partners and investment of time in these partnerships.
- Multiple, simultaneous regulatory processes underway, including TGA.



1. Starfish Medical White paper - How Much Does it Cost to Develop a Medical Device?
FOUR METHODS TO ESTIMATE MEDICAL DEVICE AND POINT OF CARE DIAGNOSTIC DEVELOPMENT COSTS

REPUTATION & DIFFERENTIATION WILL DRIVE SUCCESS



PERFORMANCE

Reader based - Sensitivity 97.3% Specificity 99.6%¹



SPEED TO RESULT

15 minutes incubation, less than 1 minute in reader,
Up to ~60 tests per hour per reader²



READING WINDOW

Valid & consistent result up to 2 hours³ after incubation.
Advantage over other tests with ~ 5-10 min windows



DATA CAPABILITY

- Stores patient result data on the reader,
- Can be interfaced to patient/customer management system,
- Touch Screen Navigation
- Simple User Interface



CONNECTIVITY

LAN & WiFi



SUITE OF TESTS


COVID-19 Antigen, COVID-19 Flu A/B Multiplex, Sepsis Family
+ Bacterial, Viral, Infectious future development

EUGENI – DELIVERS PLATFORM TO SCALE FOR MULTIPLE TESTS



Use the pandemic to gain entry into the global device based PoC Rapid Diagnostic Market through the COVID-19 RAT.
Leverage the Reader base with Multiple Differentiated Tests.*


- Multi market launch of COVID-19 RAT
- EuGeni Readers placed across global markets
- Creates users ready for new test in pipeline
- Enables stable business growth over time – targeting large high growth market.



GROWING GLOBAL MARKET PRESENCE

Growing European and SE Asian presence, with activities and planning under way for US Market entry in 2022.

- 7 Distributors signed covering 14 territories
- 13 additional distributor leads in varying stages of discussion*
- US Market Entry planned for 2022*
- Appointment of US market entry and marketing consultants – previously advisors to Ellume
- In discussions with US based clinical research organization for FDA required clinical studies



MANUFACTURING STRATEGY – SCALING TO DELIVER



- Operon (Spain) existing manufacturing with stock in inventory.
- Brisbane (Australia) strip manufacturing to come online early 2022.
- Assembly capacity to be added in Australia and Asia



20 million
STRIP CAPACITY



12 million
STRIP CAPACITY

ASSEMBLE:
8 MILLION CASSETTES
at Operon (equal to 320,000 kits)



ASSEMBLE:
12 MILLION CASSETTES
via assembly partners in
Europe, Mid-Asia, Australia
and North America.¹

ASSEMBLE:
12 MILLION CASSETTES
via assembly partners in
Europe, Mid-Asia, Australia
and North America.¹




32 million
CASSETTES
(equal to 1,280,000 kits)


OUR INTENTION IS TO OFFER SAMPLING METHODS THAT MAKE THE TEST MORE COMFORTABLE WITHOUT SACRIFICING PERFORMANCE

We have chosen not to compromise sensitivity for comfort. Our current sampling development focuses on methods which provide high viral load harvesting sites and comfort for POC testing.

EuGeni SARS-CoV-2 Ag RDT Results Using Pooled Human Spit Saliva Spiked with Inactivated Viruses
EuGeni Performance in Spit Saliva¹ Shows Excellent Results
When Antigen is Present



Sampling Method for COVID-19 Lateral Flow Immunoassay Rapid Test
Real World results show low and inconsistent viral load in Spit Saliva²





COVID-19 FLU A/B MULTIPLEX

The US CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses.¹

- Prototype finalisation on track
- Recording strong signal-to-blank ratio to improve assay's lower Limit of Detection (LoD)
- Observing no cross-reactivity between the three markers & control in the multiplexed detection
- Discussion and planning for clinical trials in US underway
- Preliminary head to head results indicating strong performance and differentiating sensitivity

UV excited EuGeni Multiplex test strip arrangement and detection signal as displayed in software for analysis




SEPSIS FAMILY OF TESTS

EuGeni platform for Sepsis - offering de-centralised quantitative diagnostics at the point of need creating significant values for the platform and AnteoTech.

- Accelerated program to deliver 'Family' of quantitative biomarker tests for Sepsis
- Dedicated development team recruited
- Speed to market increased through splitting into individual biomarkers
- Targeting emergency and hospital critical care, remote care medicine market



Example Interleukin 6
Test LoD below Clinical Cut-off Achieved
(data on file)¹



TEST	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022
1. Interleukin 6	→ Clinical	Regulatory			
2. Procalcitonin	→ Clinical	Regulatory			
Biomarker 1 & 2	→ Clinical	Regulatory			
Biomarker 1, 2 & 3	→ Clinical	Regulatory			
Other Biomarkers	→ Clinical	Regulatory			



AnteoTech

Energy

OUR APPROACH TO ANTEOX COMMERCIALISATION




ANTEOX



**Binder material
manufacturer**

Collaborator 8




**Active material
manufacturer**

Collaborator 2



- Matching of AnteoX with specific binder chemistries of collaborators
- Fine-tune AnteoX properties & facilitate process integration with collaborators
- Progress relationship to commercial level & prepare for low volume AnteoX supply



**SILICON ANODE
REFERENCE
DESIGN**



**Cross Linking Agent Providing
Enhanced Electrochemical
Performance**




**Enhances Cohesion
of the Anode**

OUTSTANDING RESULTS DRIVE PROGRESSION TO CUSTOMER DEMONSTRATIONS

AnteoX demonstrates a 26% increase in full cell cycle life (at 70% capacity retention)¹

- AnteoX anode design capacity set at substantially higher levels compared to current industry standard
- AnteoX adds 50 cycles to very high anode design capacity in full cells (+26%)



1. AnteoTech internal testing result.

PROGRESSION OF DEMONSTRATIONS



↑
Entering Trials
Request to Build Full Anode

↓

**High Power Output
Battery Manufacturer**



↑
Entering Trials
Request to Build Full Anode

↑
Demonstrations TK

↓

**EV Vehicle
Manufacturers**

↓

**Battery
Manufacturer(s)**



AnteoTech

Appendix

SNAPSHOT TODAY



AnteoTech is commercialising innovative patented technology – with revenue opportunity across two key growth sectors: Point of Care (POC) diagnostics and Lithium-ion battery market


- COVID-19 Rapid Antigen Test (RAT) launched April 2021 into growth market
- Developing COVID-19 Flu A/B for commercialisation in late 2021/early 2022
- Accelerating development of Sepsis detection test, to enter clinical trials in early 2022
- AnteoBind key component in Ellume's FDA EUA authorised COVID-19 RAT now in US market
- Growing international POC distribution network
- Developing global partnerships in battery vertical to develop silicon capacity leveraging our technology
- Financials – cash balance \$21.3M (as at 30 June 2021)



EUGENI – COVID-19 RAT - SIGNIFICANT PROGRESS IN 18 MONTHS

The EuGeni COVID-19 RAT rollout is progressing well. Key achievements to date:

- ✓ Designed, built and delivered first lateral flow test < 12 months on time & budget
- ✓ Developed EuGeni Reader Platform < 12 months
- ✓ Achieved market leading High Sensitivity & Specificity
- ✓ CE Mark Registration
- ✓ Signed 6 distributors
- ✓ Distributor onboarding, training & market planning
- ✓ Undertaking regulatory processes in 11 jurisdictions
- ✓ Commenced sales
- ✓ TGA Application in progress
- ✓ Ongoing evaluation of sample collection methods to increase patient comfort





AnteoTech Ltd (ASX:ADO)

Derek Thomson
Chief Executive Officer